Ampreloxetine clinical trials
Also written TD-9855.
How each study uses ampreloxetine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
10 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ampreloxetine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System AtrophyActive, not recruitingPhase 3Theravance BiopharmaNCT05696717Written as AmpreloxetineHow we know
- Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureTerminatedPhase 3Theravance BiopharmaNCT03829657Written as ampreloxetineHow we know
- Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureTerminatedPhase 3Theravance BiopharmaNCT04095793Written as ampreloxetineHow we know
- TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)CompletedPhase 2Theravance BiopharmaNCT02705755Written as TD-9855How we know
- Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureCompletedPhase 3Theravance BiopharmaNCT03750552Written as ampreloxetineHow we know
- A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedPhase 2Theravance BiopharmaNCT01458340Written as TD-9855How we know
- Phase 2 Study of TD-9855 to Treat FibromyalgiaCompletedPhase 2Theravance BiopharmaNCT01693692Written as TD-9855 Group 1How we know
- Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855CompletedPhase 1Theravance BiopharmaNCT04200573Written as AmpreloxetineHow we know
- TD-9855 Mass Balance StudyCompletedPhase 1Theravance BiopharmaNCT01924143Written as TD-9855How we know
- Drug-Drug Interaction (DDI) Study for TD-9855CompletedPhase 1Theravance BiopharmaNCT03432793Written as TD-9855How we know
Codes
What other systems call ampreloxetine · ClinicalTrials.gg INT000322
- MeSH (NLM) C000601820ampreloxetineOne source NLM
- UNII (FDA) 19997EZ42IAMPRELOXETINEConfirmed FDA, NLM, Wikidata
- Wikidata Q130478613ampreloxetineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166483AmpreloxetineOne source FDA
- DrugBank DB15348One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000601820 | ampreloxetine | One source NLM |
| UNII (FDA) | 19997EZ42I | AMPRELOXETINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q130478613 | ampreloxetine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166483 | Ampreloxetine | One source FDA |
| DrugBank | DB15348 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.